<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CAR-T Outcome Prediction Dashboard - DLBCL</title>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.9.1/chart.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/js/all.min.js"></script>
    <style>
/* Base styles */
* {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
}

body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
    min-height: 100vh;
}

.dashboard-container {
    max-width: 1400px;
    margin: 0 auto;
    background: white;
    min-height: 100vh;
    box-shadow: 0 0 20px rgba(0,0,0,0.1);
}

/* Header */
.dashboard-header {
    background: linear-gradient(135deg, #1e3c72 0%, #2a5298 100%);
    color: white;
    padding: 2rem 0;
    text-align: center;
}

.header-content h1 {
    font-size: 2.5rem;
    margin-bottom: 0.5rem;
    font-weight: 300;
}

.header-content p {
    font-size: 1.2rem;
    margin-bottom: 1rem;
    opacity: 0.9;
}

.therapy-badges {
    margin-top: 1rem;
    display: flex;
    justify-content: center;
    gap: 1rem;
    flex-wrap: wrap;
}

.therapy-badge {
    background: rgba(255,255,255,0.2);
    padding: 0.5rem 1rem;
    border-radius: 20px;
    font-size: 0.9rem;
    backdrop-filter: blur(10px);
}

/* Navigation */
.dashboard-nav {
    background: #2a5298;
    padding: 0;
    display: flex;
    justify-content: center;
    box-shadow: 0 2px 4px rgba(0,0,0,0.1);
    overflow-x: auto;
}

.nav-btn {
    background: none;
    border: none;
    color: #bdc3c7;
    padding: 1rem 1.5rem;
    cursor: pointer;
    transition: all 0.3s ease;
    font-size: 0.95rem;
    font-weight: 500;
    white-space: nowrap;
}

.nav-btn:hover {
    background: #1e3c72;
    color: white;
}

.nav-btn.active {
    background: #3498db;
    color: white;
}

/* Main content */
.dashboard-main {
    padding: 2rem;
}

.section-header {
    text-align: center;
    margin-bottom: 2rem;
}

.section-header h2 {
    color: #2c3e50;
    font-size: 2rem;
    margin-bottom: 0.5rem;
}

.section-header p {
    color: #7f8c8d;
    font-size: 1.1rem;
}

/* Section styles */
.dashboard-section {
    display: none;
    animation: fadeIn 0.5s ease-in;
}

.dashboard-section.active {
    display: block;
}

@keyframes fadeIn {
    from { opacity: 0; transform: translateY(10px); }
    to { opacity: 1; transform: translateY(0); }
}

/* Risk Assessment Styles */
.risk-assessment-container {
    max-width: 1200px;
    margin: 0 auto;
}

.assessment-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(500px, 1fr));
    gap: 2rem;
    margin-bottom: 2rem;
}

.parameter-card {
    background: #f8f9fa;
    padding: 1.5rem;
    border-radius: 10px;
    box-shadow: 0 4px 6px rgba(0,0,0,0.1);
    border-left: 4px solid #3498db;
}

.parameter-card h3 {
    color: #2c3e50;
    margin-bottom: 1rem;
    display: flex;
    align-items: center;
    gap: 0.5rem;
}

.input-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
    gap: 1rem;
}

.input-group {
    display: flex;
    flex-direction: column;
}

.input-group label {
    font-weight: 600;
    color: #2c3e50;
    margin-bottom: 0.5rem;
}

.input-group input,
.input-group select {
    padding: 0.75rem;
    border: 2px solid #e9ecef;
    border-radius: 5px;
    font-size: 1rem;
    transition: border-color 0.3s ease;
}

.input-group input:focus,
.input-group select:focus {
    outline: none;
    border-color: #3498db;
}

.input-group small {
    color: #6c757d;
    font-size: 0.8rem;
    margin-top: 0.25rem;
}

.assessment-actions {
    text-align: center;
    margin: 2rem 0;
}

.calculate-btn {
    background: linear-gradient(135deg, #3498db 0%, #2980b9 100%);
    color: white;
    border: none;
    padding: 1rem 2rem;
    font-size: 1.1rem;
    font-weight: 600;
    border-radius: 5px;
    cursor: pointer;
    transition: transform 0.2s ease;
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
}

.calculate-btn:hover {
    transform: translateY(-2px);
    box-shadow: 0 4px 8px rgba(0,0,0,0.2);
}

.calculate-btn.primary {
    background: linear-gradient(135deg, #e74c3c 0%, #c0392b 100%);
}

/* Results Styles */
.comprehensive-result {
    background: white;
    padding: 2rem;
    border-radius: 10px;
    margin-top: 2rem;
    box-shadow: 0 4px 6px rgba(0,0,0,0.1);
    border-left: 5px solid #e74c3c;
}

.result-grid {
    display: grid;
    grid-template-columns: 1fr 2fr;
    gap: 2rem;
    margin-bottom: 2rem;
}

.risk-card {
    text-align: center;
}

.risk-score-display {
    display: flex;
    flex-direction: column;
    align-items: center;
    gap: 1rem;
}

.risk-score {
    font-size: 3rem;
    font-weight: bold;
    color: #e74c3c;
}

.risk-category {
    font-size: 1.2rem;
    font-weight: 600;
    padding: 0.5rem 1rem;
    border-radius: 25px;
    display: inline-block;
}

.risk-category.low-risk { background: #d4edda; color: #155724; }
.risk-category.intermediate-risk { background: #fff3cd; color: #856404; }
.risk-category.high-risk { background: #f8d7da; color: #721c24; }

.outcome-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
    gap: 1rem;
}

.outcome-item {
    background: #f8f9fa;
    padding: 1rem;
    border-radius: 5px;
    display: flex;
    flex-direction: column;
    text-align: center;
}

.outcome-label {
    font-weight: 600;
    color: #2c3e50;
    margin-bottom: 0.5rem;
}

.outcome-value {
    font-size: 1.5rem;
    font-weight: bold;
    color: #3498db;
}

.risk-visualization {
    text-align: center;
}

.risk-visualization canvas {
    max-width: 400px;
    height: 200px;
}

/* CAR-HEMATOTOX Styles */
.hematotox-calculator {
    max-width: 800px;
    margin: 0 auto;
}

.calculator-info {
    margin-bottom: 2rem;
}

.info-card {
    background: #e8f4fd;
    padding: 1.5rem;
    border-radius: 10px;
    border-left: 4px solid #3498db;
}

.info-card h3 {
    color: #2c3e50;
    margin-bottom: 1rem;
}

.info-card ul {
    list-style: none;
    padding: 0;
}

.info-card li {
    padding: 0.5rem 0;
    border-bottom: 1px solid #dee2e6;
}

.info-card li:last-child {
    border-bottom: none;
}

.hematotox-inputs {
    background: #f8f9fa;
    padding: 2rem;
    border-radius: 10px;
    margin-bottom: 2rem;
}

.threshold-indicator {
    margin-top: 0.5rem;
    padding: 0.25rem 0.5rem;
    border-radius: 3px;
    font-size: 0.8rem;
    text-align: center;
}

.threshold-indicator.normal {
    background: #d4edda;
    color: #155724;
}

.threshold-indicator.abnormal {
    background: #f8d7da;
    color: #721c24;
}

.hematotox-result {
    background: white;
    padding: 2rem;
    border-radius: 10px;
    box-shadow: 0 4px 6px rgba(0,0,0,0.1);
}

.score-display {
    text-align: center;
    margin-bottom: 2rem;
}

.score-value {
    font-size: 4rem;
    font-weight: bold;
    color: #e74c3c;
}

.score-unit {
    font-size: 1.2rem;
    color: #6c757d;
    margin-left: 0.5rem;
}

.score-interpretation {
    font-size: 1.5rem;
    font-weight: 600;
    margin-top: 1rem;
    padding: 0.5rem 1rem;
    border-radius: 25px;
    display: inline-block;
}

.score-interpretation.low { background: #d4edda; color: #155724; }
.score-interpretation.intermediate { background: #fff3cd; color: #856404; }
.score-interpretation.high { background: #f8d7da; color: #721c24; }

.risk-table {
    background: #f8f9fa;
    border-radius: 8px;
    overflow: hidden;
    margin-top: 2rem;
}

.risk-row {
    display: grid;
    grid-template-columns: 1fr 1fr 1fr;
    padding: 1rem;
    border-bottom: 1px solid #dee2e6;
    align-items: center;
}

.risk-row:last-child {
    border-bottom: none;
}

.risk-score-range {
    font-weight: 600;
    color: #2c3e50;
}

.risk-level {
    padding: 0.25rem 0.75rem;
    border-radius: 15px;
    font-weight: 600;
    text-align: center;
}

.risk-level.low { background: #d4edda; color: #155724; }
.risk-level.intermediate { background: #fff3cd; color: #856404; }
.risk-level.high { background: #f8d7da; color: #721c24; }

.risk-percentage {
    text-align: right;
    font-weight: 600;
    color: #e74c3c;
}

.clinical-implications {
    margin-top: 2rem;
}

.clinical-implications h4 {
    color: #2c3e50;
    margin-bottom: 1rem;
}

.implications-content p {
    margin-bottom: 0.5rem;
    padding-left: 1rem;
}

/* References Section Styles */
.reference-category {
    margin-bottom: 3rem;
}

.reference-category h4 {
    color: #2c3e50;
    font-size: 1.3rem;
    margin-bottom: 1.5rem;
    padding-bottom: 0.5rem;
    border-bottom: 2px solid #3498db;
    display: flex;
    align-items: center;
    gap: 0.5rem;
}

.reference-list {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

.reference-item {
    background: #f8f9fa;
    padding: 1.5rem;
    border-radius: 8px;
    border-left: 4px solid #3498db;
    transition: box-shadow 0.3s ease;
}

.reference-item:hover {
    box-shadow: 0 4px 12px rgba(0,0,0,0.1);
}

.reference-content {
    position: relative;
}

.reference-title {
    font-weight: 600;
    color: #2c3e50;
    font-size: 1.1rem;
    line-height: 1.4;
    margin-bottom: 0.5rem;
}

.reference-authors {
    color: #34495e;
    font-size: 0.95rem;
    margin-bottom: 0.5rem;
}

.reference-journal {
    color: #7f8c8d;
    font-size: 0.9rem;
    margin-bottom: 0.75rem;
}

.reference-note {
    background: #e8f4fd;
    color: #2c3e50;
    padding: 0.5rem 0.75rem;
    border-radius: 4px;
    font-size: 0.85rem;
    font-style: italic;
    margin-bottom: 1rem;
    border-left: 3px solid #3498db;
}

.reference-link {
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
    background: #3498db;
    color: white;
    padding: 0.5rem 1rem;
    border-radius: 5px;
    text-decoration: none;
    font-size: 0.9rem;
    font-weight: 500;
    transition: background-color 0.3s ease;
}

.reference-link:hover {
    background: #2980b9;
    text-decoration: none;
    color: white;
}

.reference-note-box {
    background: #fff3cd;
    border: 1px solid #ffeaa7;
    border-left: 4px solid #f39c12;
    padding: 1.5rem;
    border-radius: 8px;
    margin-top: 2rem;
}

.reference-note-box h4 {
    color: #856404;
    margin-bottom: 1rem;
    display: flex;
    align-items: center;
    gap: 0.5rem;
}

.reference-note-box p {
    color: #856404;
    margin-bottom: 1rem;
    line-height: 1.6;
}

.reference-note-box p:last-child {
    margin-bottom: 0;
}

/* Toxicities Section Styles */
.toxicity-card {
    border-left-color: #e74c3c;
}

.toxicity-grading {
    margin-bottom: 2rem;
}

.toxicity-grading h4 {
    color: #2c3e50;
    margin-bottom: 1rem;
    font-size: 1.1rem;
}

.grade-table {
    display: flex;
    flex-direction: column;
    gap: 0.75rem;
}

.grade-item {
    display: grid;
    grid-template-columns: 80px 1fr;
    gap: 1rem;
    padding: 1rem;
    border-radius: 6px;
    align-items: center;
}

.grade-item.grade-1 {
    background: #d4edda;
    border-left: 4px solid #27ae60;
}

.grade-item.grade-2 {
    background: #fff3cd;
    border-left: 4px solid #f39c12;
}

.grade-item.grade-3 {
    background: #f8d7da;
    border-left: 4px solid #e74c3c;
}

.grade-item.grade-4 {
    background: #f5c6cb;
    border-left: 4px solid #721c24;
}

.grade-number {
    font-weight: bold;
    font-size: 1.1rem;
    text-align: center;
    color: #2c3e50;
}

.grade-description {
    font-size: 0.95rem;
    line-height: 1.4;
    color: #2c3e50;
}

.product-specific-notes {
    margin-top: 2rem;
}

.product-specific-notes h4 {
    color: #2c3e50;
    margin-bottom: 1rem;
    font-size: 1.1rem;
}

.product-note {
    padding: 1rem;
    margin-bottom: 0.75rem;
    border-radius: 6px;
    font-size: 0.95rem;
    line-height: 1.5;
}

.product-note.axi-cel {
    background: #fff5f5;
    border-left: 4px solid #e74c3c;
    color: #2c3e50;
}

.product-note.tisa-cel {
    background: #f0fff4;
    border-left: 4px solid #27ae60;
    color: #2c3e50;
}

.product-note.liso-cel {
    background: #f0f8ff;
    border-left: 4px solid #3498db;
    color: #2c3e50;
}

.risk-factor-card {
    background: #f8f9fa;
    padding: 1.5rem;
    border-radius: 10px;
    box-shadow: 0 4px 6px rgba(0,0,0,0.1);
    border-left: 4px solid #f39c12;
}

.risk-factor-card h4 {
    color: #2c3e50;
    margin-bottom: 1rem;
    display: flex;
    align-items: center;
    gap: 0.5rem;
}

.risk-factor-list {
    list-style: none;
    padding: 0;
    margin: 0;
}

.risk-factor-list li {
    padding: 0.5rem 0;
    border-bottom: 1px solid #dee2e6;
    font-size: 0.95rem;
    line-height: 1.4;
}

.risk-factor-list li:last-child {
    border-bottom: none;
}

.management-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(400px, 1fr));
    gap: 2rem;
    margin-bottom: 2rem;
}

.management-card {
    background: #f8f9fa;
    padding: 1.5rem;
    border-radius: 10px;
    box-shadow: 0 4px 6px rgba(0,0,0,0.1);
}

.management-card.crs-management {
    border-left: 4px solid #e74c3c;
}

.management-card.icans-management {
    border-left: 4px solid #3498db;
}

.management-card h4 {
    color: #2c3e50;
    margin-bottom: 1.5rem;
    display: flex;
    align-items: center;
    gap: 0.5rem;
}

.management-steps {
    display: flex;
    flex-direction: column;
    gap: 1rem;
}

.management-step {
    display: grid;
    grid-template-columns: 80px 1fr;
    gap: 1rem;
    padding: 1rem;
    background: white;
    border-radius: 6px;
    box-shadow: 0 2px 4px rgba(0,0,0,0.1);
}

.step-grade {
    font-weight: bold;
    color: #2c3e50;
    text-align: center;
    font-size: 1rem;
    display: flex;
    align-items: center;
    justify-content: center;
}

.step-treatment {
    font-size: 0.9rem;
    line-height: 1.4;
    color: #2c3e50;
}

.management-principles {
    display: grid;
    gap: 0.75rem;
}

.management-principles p {
    margin: 0;
    padding: 0.75rem;
    background: #f8f9fa;
    border-radius: 4px;
    border-left: 3px solid #f39c12;
}

/* Footer */
.dashboard-footer {
    background: #2c3e50;
    color: white;
    padding: 2rem 0;
    text-align: center;
    margin-top: 3rem;
}

.footer-content p {
    margin-bottom: 0.5rem;
}

.footer-content small {
    opacity: 0.8;
}

/* Responsive Design */
@media (max-width: 768px) {
    .dashboard-nav {
        flex-direction: column;
    }
    
    .nav-btn {
        padding: 0.75rem 1rem;
        width: 100%;
    }
    
    .dashboard-main {
        padding: 1rem;
    }
    
    .assessment-grid {
        grid-template-columns: 1fr;
    }
    
    .result-grid {
        grid-template-columns: 1fr;
    }
    
    .therapy-badges {
        flex-direction: column;
        align-items: center;
    }
}
    </style>
</head>
<body>
    <div class="dashboard-container">
        <!-- Header -->
        <header class="dashboard-header">
            <div class="header-content">
                <h1><i class="fas fa-dna"></i> CAR-T Outcome Prediction Dashboard</h1>
                <p>Diffuse Large B-Cell Lymphoma (DLBCL) - Anti-CD19 CAR-T Therapy</p>
                <div class="therapy-badges">
                    <span class="therapy-badge">Predictive Modeling</span>
                    <span class="therapy-badge">Evidence-Based Assessment</span>
                    <span class="therapy-badge">Clinical Decision Support</span>
                </div>
            </div>
        </header>

        <!-- Navigation -->
        <nav class="dashboard-nav">
            <button class="nav-btn active" data-section="risk-assessment">Risk Assessment</button>
            <button class="nav-btn" data-section="car-hematotox">CAR-HEMATOTOX</button>
            <button class="nav-btn" data-section="ipi-score">IPI Risk Score</button>
            <button class="nav-btn" data-section="toxicities">Toxicities</button>
            <button class="nav-btn" data-section="outcomes">Outcomes</button>
            <button class="nav-btn" data-section="references">References</button>
        </nav>

        <!-- Main Content -->
        <main class="dashboard-main">
            <!-- Risk Assessment Section -->
            <section id="risk-assessment" class="dashboard-section active">
                <div class="section-header">
                    <h2>Comprehensive Risk Assessment</h2>
                    <p>Integrated clinical, laboratory, and imaging parameters for CAR-T outcome prediction</p>
                </div>
                
                <div class="risk-assessment-container">
                    <div class="assessment-grid">
                        <!-- Clinical Parameters -->
                        <div class="parameter-card">
                            <h3><i class="fas fa-user-md"></i> Clinical Parameters</h3>
                            <div class="input-grid">
                                <div class="input-group">
                                    <label for="age">Age (years)</label>
                                    <input type="number" id="age" min="18" max="90" value="65">
                                </div>
                                <div class="input-group">
                                    <label for="ecog">ECOG Performance Status</label>
                                    <select id="ecog">
                                        <option value="0">0 - Fully active</option>
                                        <option value="1" selected>1 - Restricted in strenuous activity</option>
                                        <option value="2">2 - Ambulatory, self-care capable</option>
                                        <option value="3">3 - Limited self-care</option>
                                        <option value="4">4 - Completely disabled</option>
                                    </select>
                                </div>
                                <div class="input-group">
                                    <label for="prior-lines">Prior Lines of Therapy</label>
                                    <input type="number" id="prior-lines" min="1" max="10" value="2">
                                </div>
                                <div class="input-group">
                                    <label for="stage">Ann Arbor Stage</label>
                                    <select id="stage">
                                        <option value="1">I</option>
                                        <option value="2">II</option>
                                        <option value="3" selected>III</option>
                                        <option value="4">IV</option>
                                    </select>
                                </div>
                            </div>
                        </div>

                        <!-- Laboratory Parameters -->
                        <div class="parameter-card">
                            <h3><i class="fas fa-flask"></i> Laboratory Parameters</h3>
                            <div class="input-grid">
                                <div class="input-group">
                                    <label for="ldh">LDH (U/L)</label>
                                    <input type="number" id="ldh" min="100" max="3000" value="400">
                                    <small>Normal: 140-280 U/L</small>
                                </div>
                                <div class="input-group">
                                    <label for="crp">C-Reactive Protein (mg/L)</label>
                                    <input type="number" id="crp" min="0" max="500" step="0.1" value="15">
                                    <small>Normal: <3.0 mg/L</small>
                                </div>
                                <div class="input-group">
                                    <label for="ferritin">Ferritin (ng/mL)</label>
                                    <input type="number" id="ferritin" min="10" max="5000" value="300">
                                    <small>Normal: 12-300 ng/mL</small>
                                </div>
                                <div class="input-group">
                                    <label for="hemoglobin">Hemoglobin (g/dL)</label>
                                    <input type="number" id="hemoglobin" min="5" max="18" step="0.1" value="11.5">
                                    <small>Normal: 12-16 g/dL</small>
                                </div>
                                <div class="input-group">
                                    <label for="platelets">Platelets (×10³/μL)</label>
                                    <input type="number" id="platelets" min="10" max="800" value="150">
                                    <small>Normal: 150-450 ×10³/μL</small>
                                </div>
                                <div class="input-group">
                                    <label for="anc">Absolute Neutrophil Count (×10³/μL)</label>
                                    <input type="number" id="anc" min="0.1" max="20" step="0.1" value="2.5">
                                    <small>Normal: 1.8-7.8 ×10³/μL</small>
                                </div>
                            </div>
                        </div>

                        <!-- Imaging Parameters -->
                        <div class="parameter-card">
                            <h3><i class="fas fa-microscope"></i> Imaging & Tumor Burden</h3>
                            <div class="input-grid">
                                <div class="input-group">
                                    <label for="mtv">Metabolic Tumor Volume (mL)</label>
                                    <input type="number" id="mtv" min="0" max="2000" step="0.1" value="50">
                                    <small>High-risk: >75 mL</small>
                                </div>
                                <div class="input-group">
                                    <label for="tlg">Total Lesion Glycolysis</label>
                                    <input type="number" id="tlg" min="0" max="5000" step="1" value="200">
                                    <small>SUVmax × MTV</small>
                                </div>
                                <div class="input-group">
                                    <label for="extranodal">Extranodal Sites</label>
                                    <input type="number" id="extranodal" min="0" max="10" value="1">
                                </div>
                                <div class="input-group">
                                    <label for="largest-lesion">Largest Lesion (cm)</label>
                                    <input type="number" id="largest-lesion" min="0" max="20" step="0.1" value="5">
                                </div>
                            </div>
                        </div>

                        <!-- Genomic Parameters -->
                        <div class="parameter-card">
                            <h3><i class="fas fa-dna"></i> Genomic & Molecular Features</h3>
                            <div class="input-grid">
                                <div class="input-group">
                                    <label for="tp53">TP53 Status</label>
                                    <select id="tp53">
                                        <option value="wildtype" selected>Wild-type</option>
                                        <option value="mutated">Mutated</option>
                                        <option value="unknown">Unknown</option>
                                    </select>
                                </div>
                                <div class="input-group">
                                    <label for="myc">MYC Status</label>
                                    <select id="myc">
                                        <option value="normal" selected>Normal</option>
                                        <option value="rearranged">Rearranged</option>
                                        <option value="double-hit">Double-hit</option>
                                        <option value="unknown">Unknown</option>
                                    </select>
                                </div>
                                <div class="input-group">
                                    <label for="coo">Cell of Origin</label>
                                    <select id="coo">
                                        <option value="gcb" selected>GCB-type</option>
                                        <option value="abc">ABC-type</option>
                                        <option value="unclassified">Unclassified</option>
                                        <option value="unknown">Unknown</option>
                                    </select>
                                </div>
                                <div class="input-group">
                                    <label for="ctdna">Baseline ctDNA (copies/mL)</label>
                                    <input type="number" id="ctdna" min="0" max="100000" value="1000">
                                    <small>High-risk: >1000 copies/mL</small>
                                </div>
                            </div>
                        </div>
                    </div>
                    
                    <div class="assessment-actions">
                        <button class="calculate-btn primary" onclick="calculateComprehensiveRisk()">
                            <i class="fas fa-calculator"></i> Calculate Risk Assessment
                        </button>
                    </div>
                    
                    <div class="comprehensive-result" id="comprehensive-result" style="display: none;">
                        <div class="result-header">
                            <h3>Risk Assessment Results</h3>
                        </div>
                        <div class="result-grid">
                            <div class="risk-card">
                                <h4>Overall Risk Score</h4>
                                <div class="risk-score-display">
                                    <span class="risk-score" id="overall-score">0</span>
                                    <span class="risk-category" id="overall-category">Low Risk</span>
                                </div>
                            </div>
                            <div class="outcome-predictions">
                                <h4>Predicted Outcomes</h4>
                                <div class="outcome-grid">
                                    <div class="outcome-item">
                                        <span class="outcome-label">Complete Response</span>
                                        <span class="outcome-value" id="cr-rate">75%</span>
                                    </div>
                                    <div class="outcome-item">
                                        <span class="outcome-label">1-year PFS</span>
                                        <span class="outcome-value" id="pfs-1y">65%</span>
                                    </div>
                                    <div class="outcome-item">
                                        <span class="outcome-label">1-year OS</span>
                                        <span class="outcome-value" id="os-1y">80%</span>
                                    </div>
                                    <div class="outcome-item">
                                        <span class="outcome-label">Severe CRS Risk</span>
                                        <span class="outcome-value" id="crs-risk">15%</span>
                                    </div>
                                    <div class="outcome-item">
                                        <span class="outcome-label">Severe ICANS Risk</span>
                                        <span class="outcome-value" id="icans-risk">10%</span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="risk-visualization">
                            <canvas id="riskChart" width="400" height="200"></canvas>
                        </div>
                    </div>
                </div>
            </section>

            <!-- CAR-HEMATOTOX Section -->
            <section id="car-hematotox" class="dashboard-section">
                <div class="section-header">
                    <h2>CAR-HEMATOTOX Score</h2>
                    <p>Predicts severe cytopenias and hematologic toxicity post-CAR-T infusion</p>
                </div>
                
                <div class="hematotox-calculator">
                    <div class="calculator-info">
                        <div class="info-card">
                            <h3>Scoring Components</h3>
                            <ul>
                                <li>Hemoglobin <10 g/dL: +1 point</li>
                                <li>Platelet count <100 ×10³/μL: +1 point</li>
                                <li>CRP >30 mg/L: +1 point</li>
                                <li>Ferritin >700 ng/mL: +1 point</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="hematotox-inputs">
                        <div class="input-grid">
                            <div class="input-group">
                                <label for="hematotox-hgb">Hemoglobin (g/dL)</label>
                                <input type="number" id="hematotox-hgb" min="5" max="18" step="0.1" value="11.0">
                                <div class="threshold-indicator normal" id="hgb-threshold">
                                    <span class="threshold-text">Normal (≥10 g/dL)</span>
                                </div>
                            </div>
                            <div class="input-group">
                                <label for="hematotox-plt">Platelet Count (×10³/μL)</label>
                                <input type="number" id="hematotox-plt" min="10" max="800" value="120">
                                <div class="threshold-indicator normal" id="plt-threshold">
                                    <span class="threshold-text">Normal (≥100 ×10³/μL)</span>
                                </div>
                            </div>
                            <div class="input-group">
                                <label for="hematotox-crp">C-Reactive Protein (mg/L)</label>
                                <input type="number" id="hematotox-crp" min="0" max="500" step="0.1" value="25">
                                <div class="threshold-indicator normal" id="crp-threshold">
                                    <span class="threshold-text">Normal (≤30 mg/L)</span>
                                </div>
                            </div>
                            <div class="input-group">
                                <label for="hematotox-ferritin">Ferritin (ng/mL)</label>
                                <input type="number" id="hematotox-ferritin" min="10" max="5000" value="600">
                                <div class="threshold-indicator normal" id="ferritin-threshold">
                                    <span class="threshold-text">Normal (≤700 ng/mL)</span>
                                </div>
                            </div>
                        </div>
                        
                        <button class="calculate-btn" onclick="calculateHematotox()">
                            <i class="fas fa-calculator"></i> Calculate CAR-HEMATOTOX Score
                        </button>
                    </div>
                    
                    <div class="hematotox-result" id="hematotox-result" style="display: none;">
                        <div class="score-display">
                            <div class="score-value">
                                <span id="hematotox-score">0</span>
                                <span class="score-unit">points</span>
                            </div>
                            <div class="score-interpretation" id="hematotox-interpretation">Low Risk</div>
                        </div>
                        
                        <div class="risk-breakdown">
                            <h4>Risk Stratification</h4>
                            <div class="risk-table">
                                <div class="risk-row">
                                    <span class="risk-score-range">0-1 points</span>
                                    <span class="risk-level low">Low Risk</span>
                                    <span class="risk-percentage">~20% severe cytopenia</span>
                                </div>
                                <div class="risk-row">
                                    <span class="risk-score-range">2 points</span>
                                    <span class="risk-level intermediate">Intermediate Risk</span>
                                    <span class="risk-percentage">~45% severe cytopenia</span>
                                </div>
                                <div class="risk-row">
                                    <span class="risk-score-range">3-4 points</span>
                                    <span class="risk-level high">High Risk</span>
                                    <span class="risk-percentage">~70% severe cytopenia</span>
                                </div>
                            </div>
                        </div>
                        
                        <div class="clinical-implications">
                            <h4>Clinical Implications</h4>
                            <div class="implications-content" id="implications-content">
                                <!-- Content will be populated by JavaScript -->
                            </div>
                        </div>
                    </div>
                </div>
            </section>

            <!-- IPI Score Section -->
            <section id="ipi-score" class="dashboard-section">
                <div class="section-header">
                    <h2>IPI Risk Score</h2>
                    <p>Modified International Prognostic Index for CAR-T patient stratification</p>
                </div>
                
                <div class="hematotox-calculator">
                    <div class="calculator-info">
                        <div class="info-card">
                            <h3>Modified IPI Components</h3>
                            <ul>
                                <li>Advanced stage (III/IV): +1 point</li>
                                <li>Elevated LDH (>ULN): +1 point</li>
                                <li>Low absolute neutrophil count (<1.5): +1 point</li>
                            </ul>
                            <p style="margin-top: 1rem; font-style: italic; color: #6c757d;">
                                This adapts traditional IPI factors for CAR-T patient stratification.
                            </p>
                        </div>
                    </div>
                    
                    <div class="hematotox-inputs">
                        <div class="input-grid">
                            <div class="input-group">
                                <label for="ipi-stage">Clinical Stage</label>
                                <select id="ipi-stage">
                                    <option value="1">Stage I</option>
                                    <option value="2">Stage II</option>
                                    <option value="3" selected>Stage III</option>
                                    <option value="4">Stage IV</option>
                                </select>
                            </div>
                            <div class="input-group">
                                <label for="ipi-ldh">LDH (U/L)</label>
                                <input type="number" id="ipi-ldh" min="100" max="3000" value="400">
                                <small>ULN typically 250-280 U/L</small>
                            </div>
                            <div class="input-group">
                                <label for="ipi-anc">Absolute Neutrophil Count (×10³/μL)</label>
                                <input type="number" id="ipi-anc" min="0.1" max="20" step="0.1" value="2.5">
                            </div>
                        </div>
                        
                        <button class="calculate-btn" onclick="calculateIPI()">
                            <i class="fas fa-calculator"></i> Calculate IPI Risk Score
                        </button>
                    </div>
                    
                    <div class="hematotox-result" id="ipi-result" style="display: none;">
                        <div class="score-display">
                            <div class="score-value">
                                <span id="ipi-score-value">0</span>
                                <span class="score-unit">points</span>
                            </div>
                            <div class="score-interpretation" id="ipi-risk-group">Low Risk</div>
                        </div>
                        
                        <div class="clinical-implications">
                            <h4>Expected Outcomes by Risk Group</h4>
                            <div class="risk-table">
                                <div class="risk-row">
                                    <span class="risk-score-range">Low Risk (0-1)</span>
                                    <span class="risk-level">1-year PFS: ~70%</span>
                                    <span class="risk-percentage">CR Rate: ~80%</span>
                                </div>
                                <div class="risk-row">
                                    <span class="risk-score-range">Intermediate Risk (2)</span>
                                    <span class="risk-level">1-year PFS: ~55%</span>
                                    <span class="risk-percentage">CR Rate: ~65%</span>
                                </div>
                                <div class="risk-row">
                                    <span class="risk-score-range">High Risk (3)</span>
                                    <span class="risk-level">1-year PFS: ~35%</span>
                                    <span class="risk-percentage">CR Rate: ~45%</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Toxicities Section -->
            <section id="toxicities" class="dashboard-section">
                <div class="section-header">
                    <h2>CAR-T Related Toxicities</h2>
                    <p>Product-specific CRS and ICANS profiles, grading, and management</p>
                </div>
                
                <div class="risk-assessment-container">
                    <!-- Toxicity Overview -->
                    <div class="comprehensive-result" style="display: block; margin-bottom: 2rem;">
                        <div class="result-header">
                            <h3>Toxicity Comparison by Product</h3>
                        </div>
                        
                        <div style="overflow-x: auto; margin-bottom: 2rem;">
                            <table style="width: 100%; border-collapse: collapse; background: white;">
                                <thead>
                                    <tr style="background: #f8f9fa;">
                                        <th style="padding: 1rem; border: 1px solid #dee2e6; text-align: left;">Product</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Any Grade CRS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Grade ≥3 CRS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Any Grade ICANS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Grade ≥3 ICANS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Median Onset CRS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Median Duration CRS</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600; background: #fff5f5;">Axicabtagene ciloleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c; font-weight: 600;">93%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c; font-weight: 600;">13%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c; font-weight: 600;">64%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c; font-weight: 600;">28%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">2 days</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">7 days</td>
                                    </tr>
                                    <tr style="background: #f8f9fa;">
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600; background: #f0fff4;">Tisagenlecleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">58%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">6%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #f39c12; font-weight: 600;">21%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">7.4%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">3 days</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">8 days</td>
                                    </tr>
                                    <tr>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600; background: #f0f8ff;">Lisocabtagene maraleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #f39c12; font-weight: 600;">42%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">2%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #f39c12; font-weight: 600;">30%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">10%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">1 day</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">5 days</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>

                    <!-- CRS Section -->
                    <div class="assessment-grid">
                        <div class="parameter-card toxicity-card">
                            <h3><i class="fas fa-thermometer-full"></i> Cytokine Release Syndrome (CRS)</h3>
                            
                            <div class="toxicity-grading">
                                <h4>ASTCT Grading Criteria</h4>
                                <div class="grade-table">
                                    <div class="grade-item grade-1">
                                        <div class="grade-number">Grade 1</div>
                                        <div class="grade-description">
                                            <strong>Fever ≥38°C</strong><br>
                                            No hypotension, no hypoxia
                                        </div>
                                    </div>
                                    <div class="grade-item grade-2">
                                        <div class="grade-number">Grade 2</div>
                                        <div class="grade-description">
                                            <strong>Fever + Hypotension</strong><br>
                                            OR Hypoxia requiring low-flow O₂ (≤6L/min)
                                        </div>
                                    </div>
                                    <div class="grade-item grade-3">
                                        <div class="grade-number">Grade 3</div>
                                        <div class="grade-description">
                                            <strong>Fever + Hypotension requiring vasopressors</strong><br>
                                            OR Hypoxia requiring high-flow O₂ or BiPAP
                                        </div>
                                    </div>
                                    <div class="grade-item grade-4">
                                        <div class="grade-number">Grade 4</div>
                                        <div class="grade-description">
                                            <strong>Life-threatening</strong><br>
                                            Vasopressors + mechanical ventilation
                                        </div>
                                    </div>
                                </div>
                            </div>

                            <div class="product-specific-notes">
                                <h4>Product-Specific Insights</h4>
                                <div class="product-note axi-cel">
                                    <strong>Axicabtagene ciloleucel:</strong> Highest CRS rates (93% any grade), early onset (day 2), associated with robust CAR-T expansion. CD28 costimulation may contribute to rapid, intense cytokine release.
                                </div>
                                <div class="product-note tisa-cel">
                                    <strong>Tisagenlecleucel:</strong> Moderate CRS rates (58% any grade), slightly delayed onset (day 3). 4-1BB costimulation associated with more controlled inflammatory response.
                                </div>
                                <div class="product-note liso-cel">
                                    <strong>Lisocabtagene maraleucel:</strong> Lowest CRS rates (42% any grade), earliest onset (day 1) but shorter duration. Controlled IL-6 release profile may contribute to manageable toxicity.
                                </div>
                            </div>
                        </div>

                        <!-- ICANS Section -->
                        <div class="parameter-card toxicity-card">
                            <h3><i class="fas fa-brain"></i> Immune Cell-Associated Neurotoxicity (ICANS)</h3>
                            
                            <div class="toxicity-grading">
                                <h4>ASTCT Grading Criteria</h4>
                                <div class="grade-table">
                                    <div class="grade-item grade-1">
                                        <div class="grade-number">Grade 1</div>
                                        <div class="grade-description">
                                            <strong>ICE Score: 7-9</strong><br>
                                            Mild cognitive impairment, no symptoms requiring intervention
                                        </div>
                                    </div>
                                    <div class="grade-item grade-2">
                                        <div class="grade-number">Grade 2</div>
                                        <div class="grade-description">
                                            <strong>ICE Score: 3-6</strong><br>
                                            Moderate cognitive impairment limiting ADLs
                                        </div>
                                    </div>
                                    <div class="grade-item grade-3">
                                        <div class="grade-number">Grade 3</div>
                                        <div class="grade-description">
                                            <strong>ICE Score: 0-2</strong><br>
                                            Severe cognitive impairment, hospitalization required
                                        </div>
                                    </div>
                                    <div class="grade-item grade-4">
                                        <div class="grade-number">Grade 4</div>
                                        <div class="grade-description">
                                            <strong>Life-threatening</strong><br>
                                            Seizures, cerebral edema, motor weakness
                                        </div>
                                    </div>
                                </div>
                            </div>

                            <div class="product-specific-notes">
                                <h4>Product-Specific Insights</h4>
                                <div class="product-note axi-cel">
                                    <strong>Axicabtagene ciloleucel:</strong> Highest ICANS rates (64% any grade, 28% grade ≥3). Often concurrent with CRS. Median onset day 4-5, can be prolonged and severe.
                                </div>
                                <div class="product-note tisa-cel">
                                    <strong>Tisagenlecleucel:</strong> Lower ICANS rates (21% any grade, 7.4% grade ≥3). Less frequent concurrent CRS. May have delayed onset relative to CRS.
                                </div>
                                <div class="product-note liso-cel">
                                    <strong>Lisocabtagene maraleucel:</strong> Moderate ICANS rates (30% any grade, 10% grade ≥3). Balanced toxicity profile with manageable neurotoxicity.
                                </div>
                            </div>
                        </div>
                    </div>

                    <!-- Risk Factors -->
                    <div class="comprehensive-result" style="display: block; margin-top: 2rem;">
                        <div class="result-header">
                            <h3>Risk Factors for Severe Toxicities</h3>
                        </div>
                        
                        <div class="assessment-grid">
                            <div class="risk-factor-card">
                                <h4><i class="fas fa-exclamation-triangle"></i> High-Risk Factors for Severe CRS</h4>
                                <ul class="risk-factor-list">
                                    <li><strong>High tumor burden:</strong> Elevated LDH, large tumor mass, high MTV</li>
                                    <li><strong>Inflammatory state:</strong> Elevated CRP, ferritin, IL-6</li>
                                    <li><strong>Product type:</strong> CD28-based CARs (axi-cel) > 4-1BB CARs</li>
                                    <li><strong>CAR-T expansion:</strong> High peak expansion correlates with CRS severity</li>
                                    <li><strong>Age:</strong> Younger patients may have more robust inflammatory responses</li>
                                    <li><strong>Thrombocytopenia:</strong> Platelet count <100K associated with severe CRS</li>
                                </ul>
                            </div>
                            
                            <div class="risk-factor-card">
                                <h4><i class="fas fa-brain"></i> High-Risk Factors for Severe ICANS</h4>
                                <ul class="risk-factor-list">
                                    <li><strong>Concurrent severe CRS:</strong> Grade ≥3 CRS increases ICANS risk</li>
                                    <li><strong>Peak CAR-T levels:</strong> Very high expansion associated with neurotoxicity</li>
                                    <li><strong>CNS involvement:</strong> History of CNS lymphoma</li>
                                    <li><strong>Age extremes:</strong> Very young or elderly patients</li>
                                    <li><strong>Baseline neurologic issues:</strong> Prior CNS infections, seizures</li>
                                    <li><strong>Bridging therapy:</strong> CNS-penetrating agents may increase risk</li>
                                </ul>
                            </div>
                        </div>
                    </div>

                    <!-- Management Guidelines -->
                    <div class="comprehensive-result" style="display: block; margin-top: 2rem;">
                        <div class="result-header">
                            <h3>Management Guidelines</h3>
                        </div>
                        
                        <div class="management-grid">
                            <div class="management-card crs-management">
                                <h4><i class="fas fa-stethoscope"></i> CRS Management</h4>
                                <div class="management-steps">
                                    <div class="management-step">
                                        <div class="step-grade">Grade 1</div>
                                        <div class="step-treatment">
                                            <strong>Supportive care:</strong><br>
                                            • Antipyretics, fluids<br>
                                            • Monitor closely<br>
                                            • No tocilizumab unless prolonged
                                        </div>
                                    </div>
                                    <div class="management-step">
                                        <div class="step-grade">Grade 2</div>
                                        <div class="step-treatment">
                                            <strong>Tocilizumab consideration:</strong><br>
                                            • 8 mg/kg IV (max 800mg)<br>
                                            • Vasopressors if needed<br>
                                            • O₂ support
                                        </div>
                                    </div>
                                    <div class="management-step">
                                        <div class="step-grade">Grade 3-4</div>
                                        <div class="step-treatment">
                                            <strong>Aggressive intervention:</strong><br>
                                            • Tocilizumab 8 mg/kg IV<br>
                                            • Consider corticosteroids<br>
                                            • ICU-level care
                                        </div>
                                    </div>
                                </div>
                            </div>
                            
                            <div class="management-card icans-management">
                                <h4><i class="fas fa-hospital"></i> ICANS Management</h4>
                                <div class="management-steps">
                                    <div class="management-step">
                                        <div class="step-grade">Grade 1</div>
                                        <div class="step-treatment">
                                            <strong>Monitoring:</strong><br>
                                            • Neurologic assessments q8h<br>
                                            • ICE score monitoring<br>
                                            • Seizure precautions
                                        </div>
                                    </div>
                                    <div class="management-step">
                                        <div class="step-grade">Grade 2</div>
                                        <div class="step-treatment">
                                            <strong>Corticosteroids:</strong><br>
                                            • Dexamethasone 10mg IV q6h<br>
                                            • Neurologic monitoring<br>
                                            • MRI if worsening
                                        </div>
                                    </div>
                                    <div class="management-step">
                                        <div class="step-grade">Grade 3-4</div>
                                        <div class="step-treatment">
                                            <strong>High-dose steroids:</strong><br>
                                            • Methylprednisolone 1000mg/day<br>
                                            • Anti-seizure prophylaxis<br>
                                            • Intensive monitoring
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                        
                        <div class="reference-note-box">
                            <h4><i class="fas fa-info-circle"></i> Key Management Principles</h4>
                            <div class="management-principles">
                                <p><strong>Timing is critical:</strong> Early recognition and intervention improve outcomes. CRS typically precedes ICANS.</p>
                                <p><strong>Tocilizumab considerations:</strong> Crosses blood-brain barrier poorly; may not prevent ICANS. Can be repeated if needed.</p>
                                <p><strong>Corticosteroid use:</strong> Reserved for ICANS or refractory CRS. May impact CAR-T persistence, but life-saving when needed.</p>
                                <p><strong>Product differences:</strong> Understanding product-specific toxicity profiles helps anticipate and prepare for management needs.</p>
                            </div>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Outcomes Section -->
            <section id="outcomes" class="dashboard-section">
                <div class="section-header">
                    <h2>CAR-T Product Comparison</h2>
                    <p>Clinical trial outcomes across different CAR-T products</p>
                </div>
                
                <div class="risk-assessment-container">
                    <div class="comprehensive-result" style="display: block;">
                        <div class="result-header">
                            <h3>Pivotal Trial Outcomes</h3>
                        </div>
                        
                        <div style="overflow-x: auto; margin-bottom: 2rem;">
                            <table style="width: 100%; border-collapse: collapse; background: white;">
                                <thead>
                                    <tr style="background: #f8f9fa;">
                                        <th style="padding: 1rem; border: 1px solid #dee2e6; text-align: left;">Product</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Trial</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">ORR</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">CR Rate</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Median PFS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Grade ≥3 CRS</th>
                                        <th style="padding: 1rem; border: 1px solid #dee2e6;">Grade ≥3 ICANS</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600;">Axicabtagene ciloleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">ZUMA-1</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">82%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">54%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">5.8 mo</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c;">13%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #e74c3c;">28%</td>
                                    </tr>
                                    <tr style="background: #f8f9fa;">
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600;">Tisagenlecleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">JULIET</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">53%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">39%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">4.1 mo</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60;">6%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60;">7.4%</td>
                                    </tr>
                                    <tr>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; font-weight: 600;">Lisocabtagene maraleucel</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">TRANSCEND</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">73%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60; font-weight: 600;">53%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6;">NR</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60;">2%</td>
                                        <td style="padding: 1rem; border: 1px solid #dee2e6; color: #27ae60;">10%</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        
                        <div class="outcome-grid">
                            <div class="outcome-item">
                                <span class="outcome-label">Key Insights</span>
                                <div style="text-align: left; margin-top: 1rem;">
                                    <p style="margin-bottom: 0.5rem;">• Axicabtagene ciloleucel shows highest response rates but increased toxicity</p>
                                    <p style="margin-bottom: 0.5rem;">• Tisagenlecleucel has the most favorable safety profile</p>
                                    <p style="margin-bottom: 0.5rem;">• Lisocabtagene maraleucel balances efficacy with manageable toxicity</p>
                                    <p>• All products show durable responses in ~40% of patients</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </section>

            <!-- References Section -->
            <section id="references" class="dashboard-section">
                <div class="section-header">
                    <h2>Key Clinical References</h2>
                    <p>Foundational studies and evidence base for CAR-T outcome prediction</p>
                </div>
                
                <div class="risk-assessment-container">
                    <div class="comprehensive-result" style="display: block;">
                        <div class="result-header">
                            <h3>Pivotal Clinical Trials</h3>
                        </div>
                        
                        <div class="reference-category">
                            <h4><i class="fas fa-flask"></i> Foundation Studies - Product Approvals</h4>
                            <div class="reference-list">
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma</div>
                                        <div class="reference-authors">Neelapu SS, Locke FL, Bartlett NL, et al.</div>
                                        <div class="reference-journal"><em>N Engl J Med</em>. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447</div>
                                        <div class="reference-note">ZUMA-1 Trial - First FDA approval for CAR-T therapy in LBCL</div>
                                        <a href="https://pubmed.ncbi.nlm.nih.gov/29226797/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PubMed
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET)</div>
                                        <div class="reference-authors">Schuster SJ, Tam CS, Borchmann P, et al.</div>
                                        <div class="reference-journal"><em>Lancet Oncol</em>. 2021;22(10):1403-1415. doi:10.1016/S1470-2045(21)00375-2</div>
                                        <div class="reference-note">JULIET Trial - Tisagenlecleucel long-term follow-up data</div>
                                        <a href="https://pubmed.ncbi.nlm.nih.gov/34516954/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PubMed
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001)</div>
                                        <div class="reference-authors">Abramson JS, Palomba ML, Gordon LI, et al.</div>
                                        <div class="reference-journal"><em>Lancet</em>. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-X</div>
                                        <div class="reference-note">TRANSCEND Trial - Lisocabtagene maraleucel registration study</div>
                                        <a href="https://pubmed.ncbi.nlm.nih.gov/32888407/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PubMed
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study</div>
                                        <div class="reference-authors">Kamdar M, Solomon SR, Arnason J, et al.</div>
                                        <div class="reference-journal"><em>J Clin Oncol</em>. 2025;43(24):2671-2678. doi:10.1200/JCO-25-00399</div>
                                        <div class="reference-note">TRANSFORM Trial - Second-line CAR-T therapy randomized study</div>
                                        <a href="https://ascopubs.org/doi/10.1200/JCO-25-00399" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> ASCO Publications
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="reference-category">
                            <h4><i class="fas fa-chart-line"></i> Biomarkers & Predictive Models</h4>
                            <div class="reference-list">
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma</div>
                                        <div class="reference-authors">Raj SS, Fei T, Fried S, et al.</div>
                                        <div class="reference-journal"><em>Nat Med</em>. 2025;31:1183-1194. doi:10.1038/s41591-025-03532-x</div>
                                        <div class="reference-note">InflaMix model - Pre-treatment inflammatory signature predicting outcomes</div>
                                        <a href="https://doi.org/10.1038/s41591-025-03532-x" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> Nature Medicine
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma</div>
                                        <div class="reference-authors">Rejeski K, Perez A, Sesques P, et al.</div>
                                        <div class="reference-journal"><em>Blood</em>. 2021;138(24):2499-2513. doi:10.1182/blood.2020010543</div>
                                        <div class="reference-note">CAR-HEMATOTOX score - Predicting severe cytopenias post-CAR-T</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8893508/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy</div>
                                        <div class="reference-authors">Zandaki D, Selukar S, Bi Y, et al.</div>
                                        <div class="reference-journal"><em>Blood Adv</em>. 2025;9(2):270-279. doi:10.1182/bloodadvances.2024014027</div>
                                        <div class="reference-note">EASIX/m-EASIX scores - Toxicity prediction models</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11782822/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity</div>
                                        <div class="reference-authors">Greenbaum U, Strati P, Saliba RM, et al.</div>
                                        <div class="reference-journal"><em>Blood Adv</em>. 2021;5(14):2799-2806. doi:10.1182/bloodadvances.2021004575</div>
                                        <div class="reference-note">Enhanced EASIX model with inflammatory markers</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8341350/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="reference-category">
                            <h4><i class="fas fa-microscope"></i> Mechanistic & Prognostic Studies</h4>
                            <div class="reference-list">
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy</div>
                                        <div class="reference-authors">Kochenderfer JN, Somerville RPT, Lu T, et al.</div>
                                        <div class="reference-journal"><em>Mol Ther</em>. 2017;25(10):2245-2253. doi:10.1016/j.ymthe.2017.07.004</div>
                                        <div class="reference-note">Early mechanistic insights into CAR-T persistence and durability</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5628864/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma</div>
                                        <div class="reference-authors">Gong IY, Tran D, Saibil S, et al.</div>
                                        <div class="reference-journal"><em>Hemasphere</em>. 2024;8(8):e130. doi:10.1002/hem3.130</div>
                                        <div class="reference-note">Comprehensive biomarker analysis for outcome prediction</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11339649/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy</div>
                                        <div class="reference-authors">Tedesco VE, Mohan C.</div>
                                        <div class="reference-journal"><em>J Immunol</em>. 2021;206(7):1561-1568. doi:10.4049/jimmunol.2001249</div>
                                        <div class="reference-note">CRS prediction biomarkers and mechanisms</div>
                                        <a href="https://doi.org/10.4049/jimmunol.2001249" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> Journal of Immunology
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="reference-category">
                            <h4><i class="fas fa-book-medical"></i> Reviews & Meta-Analyses</h4>
                            <div class="reference-list">
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma</div>
                                        <div class="reference-authors">Schleifenbaum JK, Heger JM, Jost J, et al.</div>
                                        <div class="reference-journal"><em>J Cancer Res Clin Oncol</em>. 2025;151:203. doi:10.1007/s00432-025-06249-z</div>
                                        <div class="reference-note">Comprehensive systematic review of prognostic factors</div>
                                        <a href="https://doi.org/10.1007/s00432-025-06249-z" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> Journal Link
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas</div>
                                        <div class="reference-authors">Ho C, Svoboda J.</div>
                                        <div class="reference-journal"><em>Transplant Cell Ther</em>. 2021;27(3):195-196. doi:10.1016/j.jtct.2021.02.005</div>
                                        <div class="reference-note">Clinical perspective on outcome prediction strategies</div>
                                        <a href="https://pubmed.ncbi.nlm.nih.gov/33781514/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PubMed
                                        </a>
                                    </div>
                                </div>
                                
                                <div class="reference-item">
                                    <div class="reference-content">
                                        <div class="reference-title">A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma</div>
                                        <div class="reference-authors">Shouse G, Kaempf A, Gordon MJ, et al.</div>
                                        <div class="reference-journal"><em>Blood Adv</em>. 2023;7(14):3516-3529. doi:10.1182/bloodadvances.2022009309</div>
                                        <div class="reference-note">Severe4 comorbidity index validation study</div>
                                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10362276/" target="_blank" class="reference-link">
                                            <i class="fas fa-external-link-alt"></i> PMC
                                        </a>
                                    </div>
                                </div>
                            </div>
                        </div>
                        
                        <div class="reference-note-box">
                            <h4><i class="fas fa-info-circle"></i> Usage Note</h4>
                            <p>These references form the evidence base for the predictive models and scoring systems implemented in this dashboard. The multi-layered framework synthesizes findings from these studies to provide comprehensive outcome predictions. All calculations are based on published algorithms and validated scoring systems.</p>
                            <p><strong>Clinical Disclaimer:</strong> This tool is for educational and research purposes. Clinical decisions should always involve direct consultation with qualified healthcare providers and consideration of individual patient factors not captured in these models.</p>
                        </div>
                    </div>
                </div>
            </section>
        </main>

        <!-- Footer -->
        <footer class="dashboard-footer">
            <div class="footer-content">
                <p>&copy; 2024 CAR-T Outcome Prediction Dashboard | Based on clinical evidence from ZUMA-1, JULIET, and TRANSCEND trials</p>
                <p><small>For research and educational purposes. Not for clinical decision-making without physician consultation.</small></p>
            </div>
        </footer>
    </div>

    <script>
// Global variables for charts
let riskChart = null;

// Initialize dashboard
document.addEventListener('DOMContentLoaded', function() {
    initializeNavigation();
    setupInputListeners();
    updateThresholdIndicators();
});

// Navigation functionality
function initializeNavigation() {
    const navButtons = document.querySelectorAll('.nav-btn');
    const sections = document.querySelectorAll('.dashboard-section');
    
    navButtons.forEach(button => {
        button.addEventListener('click', function() {
            const targetSection = this.getAttribute('data-section');
            
            // Update active nav button
            navButtons.forEach(btn => btn.classList.remove('active'));
            this.classList.add('active');
            
            // Update active section
            sections.forEach(section => section.classList.remove('active'));
            document.getElementById(targetSection).classList.add('active');
        });
    });
}

// Setup input listeners for real-time updates
function setupInputListeners() {
    // CAR-HEMATOTOX threshold indicators
    const hematotoxInputs = ['hematotox-hgb', 'hematotox-plt', 'hematotox-crp', 'hematotox-ferritin'];
    hematotoxInputs.forEach(id => {
        const input = document.getElementById(id);
        if (input) {
            input.addEventListener('input', updateThresholdIndicators);
        }
    });
}

// Update threshold indicators for CAR-HEMATOTOX
function updateThresholdIndicators() {
    const hgb = parseFloat(document.getElementById('hematotox-hgb')?.value) || 0;
    const plt = parseFloat(document.getElementById('hematotox-plt')?.value) || 0;
    const crp = parseFloat(document.getElementById('hematotox-crp')?.value) || 0;
    const ferritin = parseFloat(document.getElementById('hematotox-ferritin')?.value) || 0;
    
    // Update threshold indicators
    updateThresholdStatus('hgb-threshold', hgb < 10, 'Hemoglobin', '≥10 g/dL', '<10 g/dL (+1 pt)');
    updateThresholdStatus('plt-threshold', plt < 100, 'Platelets', '≥100 ×10³/μL', '<100 ×10³/μL (+1 pt)');
    updateThresholdStatus('crp-threshold', crp > 30, 'CRP', '≤30 mg/L', '>30 mg/L (+1 pt)');
    updateThresholdStatus('ferritin-threshold', ferritin > 700, 'Ferritin', '≤700 ng/mL', '>700 ng/mL (+1 pt)');
}

function updateThresholdStatus(elementId, isAbnormal, label, normalText, abnormalText) {
    const element = document.getElementById(elementId);
    if (element) {
        element.className = `threshold-indicator ${isAbnormal ? 'abnormal' : 'normal'}`;
        element.innerHTML = `<span class="threshold-text">${isAbnormal ? abnormalText : normalText}</span>`;
    }
}

// Comprehensive Risk Assessment Calculator
function calculateComprehensiveRisk() {
    // Get all input values
    const age = parseInt(document.getElementById('age').value);
    const ecog = parseInt(document.getElementById('ecog').value);
    const priorLines = parseInt(document.getElementById('prior-lines').value);
    const stage = parseInt(document.getElementById('stage').value);
    const ldh = parseInt(document.getElementById('ldh').value);
    const crp = parseFloat(document.getElementById('crp').value);
    const ferritin = parseInt(document.getElementById('ferritin').value);
    const hemoglobin = parseFloat(document.getElementById('hemoglobin').value);
    const platelets = parseInt(document.getElementById('platelets').value);
    const anc = parseFloat(document.getElementById('anc').value);
    const mtv = parseFloat(document.getElementById('mtv').value);
    const tlg = parseFloat(document.getElementById('tlg').value);
    const extranodal = parseInt(document.getElementById('extranodal').value);
    const largestLesion = parseFloat(document.getElementById('largest-lesion').value);
    const tp53 = document.getElementById('tp53').value;
    const myc = document.getElementById('myc').value;
    const coo = document.getElementById('coo').value;
    const ctdna = parseInt(document.getElementById('ctdna').value);
    
    // Calculate risk score based on the multi-layered framework from the thesis
    let riskScore = 0;
    let riskFactors = [];
    
    // Layer 1: Pre-treatment factors
    
    // Clinical factors
    if (age > 65) {
        riskScore += 1;
        riskFactors.push('Age >65');
    }
    if (ecog >= 2) {
        riskScore += 2;
        riskFactors.push('ECOG ≥2');
    }
    if (priorLines >= 3) {
        riskScore += 1;
        riskFactors.push('≥3 prior lines');
    }
    if (stage >= 3) {
        riskScore += 1;
        riskFactors.push('Advanced stage');
    }
    
    // Laboratory factors (InflaMix components)
    if (ldh > 280) {
        riskScore += 1;
        riskFactors.push('Elevated LDH');
    }
    if (crp > 30) {
        riskScore += 2;
        riskFactors.push('High CRP (inflammatory signature)');
    }
    if (ferritin > 700) {
        riskScore += 1;
        riskFactors.push('High ferritin');
    }
    if (hemoglobin < 10) {
        riskScore += 1;
        riskFactors.push('Anemia');
    }
    if (platelets < 100) {
        riskScore += 1;
        riskFactors.push('Thrombocytopenia');
    }
    if (anc < 1.5) {
        riskScore += 1;
        riskFactors.push('Neutropenia');
    }
    
    // Tumor burden (high-risk thresholds from thesis)
    if (mtv > 75) {
        riskScore += 2;
        riskFactors.push('High MTV (>75 mL)');
    }
    if (tlg > 300) {
        riskScore += 1;
        riskFactors.push('High TLG');
    }
    if (extranodal > 2) {
        riskScore += 1;
        riskFactors.push('Multiple extranodal sites');
    }
    if (largestLesion > 7) {
        riskScore += 1;
        riskFactors.push('Bulky disease');
    }
    
    // Genomic factors (Layer 2 influence)
    if (tp53 === 'mutated') {
        riskScore += 2;
        riskFactors.push('TP53 mutation (resistance factor)');
    }
    if (myc === 'double-hit') {
        riskScore += 2;
        riskFactors.push('Double-hit lymphoma');
    } else if (myc === 'rearranged') {
        riskScore += 1;
        riskFactors.push('MYC rearrangement');
    }
    if (coo === 'abc') {
        riskScore += 1;
        riskFactors.push('ABC subtype');
    }
    if (ctdna > 1000) {
        riskScore += 1;
        riskFactors.push('High baseline ctDNA');
    }
    
    // Determine risk category and outcomes based on clinical evidence from thesis
    let riskCategory, crRate, pfs1y, os1y, crsRisk, icansRisk;
    
    if (riskScore <= 3) {
        riskCategory = 'Low Risk';
        crRate = 75; // Based on ZUMA-1 favorable subset
        pfs1y = 70;
        os1y = 85;
        crsRisk = 8;
        icansRisk = 5;
    } else if (riskScore <= 7) {
        riskCategory = 'Intermediate Risk';
        crRate = 60; // Intermediate outcomes
        pfs1y = 50;
        os1y = 70;
        crsRisk = 15;
        icansRisk = 12;
    } else {
        riskCategory = 'High Risk';
        crRate = 40; // High-risk patients from thesis
        pfs1y = 30;
        os1y = 50;
        crsRisk = 25;
        icansRisk = 20;
    }
    
    // Update display
    document.getElementById('overall-score').textContent = riskScore;
    document.getElementById('overall-category').textContent = riskCategory;
    document.getElementById('overall-category').className = `risk-category ${riskCategory.toLowerCase().replace(' ', '-')}`;
    
    document.getElementById('cr-rate').textContent = `${crRate}%`;
    document.getElementById('pfs-1y').textContent = `${pfs1y}%`;
    document.getElementById('os-1y').textContent = `${os1y}%`;
    document.getElementById('crs-risk').textContent = `${crsRisk}%`;
    document.getElementById('icans-risk').textContent = `${icansRisk}%`;
    
    // Create risk visualization
    createRiskChart(riskScore, riskCategory, riskFactors);
    
    // Show results
    document.getElementById('comprehensive-result').style.display = 'block';
    document.getElementById('comprehensive-result').scrollIntoView({ behavior: 'smooth' });
}

// Create risk visualization chart
function createRiskChart(riskScore, riskCategory, riskFactors) {
    const ctx = document.getElementById('riskChart').getContext('2d');
    
    if (riskChart) {
        riskChart.destroy();
    }
    
    const maxScore = 20; // Maximum possible score based on all factors
    
    let color;
    if (riskScore <= 3) color = '#27ae60';
    else if (riskScore <= 7) color = '#f39c12';
    else color = '#e74c3c';
    
    riskChart = new Chart(ctx, {
        type: 'doughnut',
        data: {
            labels: ['Risk Score', 'Remaining'],
            datasets: [{
                data: [riskScore, maxScore - riskScore],
                backgroundColor: [color, '#ecf0f1'],
                borderWidth: 2,
                borderColor: '#fff'
            }]
        },
        options: {
            responsive: true,
            maintainAspectRatio: false,
            plugins: {
                legend: {
                    display: false
                },
                title: {
                    display: true,
                    text: `Risk Score: ${riskScore}/${maxScore} (${riskCategory})`,
                    font: {
                        size: 16,
                        weight: 'bold'
                    }
                }
            },
            cutout: '70%'
        }
    });
}

// CAR-HEMATOTOX Score Calculator
function calculateHematotox() {
    const hgb = parseFloat(document.getElementById('hematotox-hgb').value);
    const plt = parseFloat(document.getElementById('hematotox-plt').value);
    const crp = parseFloat(document.getElementById('hematotox-crp').value);
    const ferritin = parseFloat(document.getElementById('hematotox-ferritin').value);
    
    let score = 0;
    let scoringComponents = [];
    
    if (hgb < 10) {
        score += 1;
        scoringComponents.push('Hemoglobin <10 g/dL');
    }
    if (plt < 100) {
        score += 1;
        scoringComponents.push('Platelets <100 ×10³/μL');
    }
    if (crp > 30) {
        score += 1;
        scoringComponents.push('CRP >30 mg/L');
    }
    if (ferritin > 700) {
        score += 1;
        scoringComponents.push('Ferritin >700 ng/mL');
    }
    
    let riskLevel, riskClass, implications;
    
    if (score <= 1) {
        riskLevel = 'Low Risk';
        riskClass = 'low';
        implications = [
            'Low risk of severe cytopenia (~20%)',
            'Standard monitoring protocols sufficient',
            'Shorter hospitalization expected',
            'Lower transfusion requirements',
            'Good candidate for outpatient monitoring'
        ];
    } else if (score === 2) {
        riskLevel = 'Intermediate Risk';
        riskClass = 'intermediate';
        implications = [
            'Moderate risk of severe cytopenia (~45%)',
            'Enhanced monitoring recommended',
            'Prepare for possible extended hospitalization',
            'Monitor closely for infectious complications',
            'Consider prophylactic measures'
        ];
    } else {
        riskLevel = 'High Risk';
        riskClass = 'high';
        implications = [
            'High risk of severe cytopenia (~70%)',
            'Intensive monitoring required',
            'Extended hospitalization likely',
            'Consider prophylactic growth factors',
            'Close infectious disease consultation',
            'Aggressive supportive care planning'
        ];
    }
    
    // Update display
    document.getElementById('hematotox-score').textContent = score;
    document.getElementById('hematotox-interpretation').textContent = riskLevel;
    document.getElementById('hematotox-interpretation').className = `score-interpretation ${riskClass}`;
    
    // Update implications
    const implicationsElement = document.getElementById('implications-content');
    implicationsElement.innerHTML = implications.map(item => `<p>• ${item}</p>`).join('');
    
    // Show results
    document.getElementById('hematotox-result').style.display = 'block';
    document.getElementById('hematotox-result').scrollIntoView({ behavior: 'smooth' });
}

// IPI Score Calculator
function calculateIPI() {
    const stage = parseInt(document.getElementById('ipi-stage').value);
    const ldh = parseInt(document.getElementById('ipi-ldh').value);
    const anc = parseFloat(document.getElementById('ipi-anc').value);
    
    let score = 0;
    let components = [];
    
    // Advanced stage (III/IV)
    if (stage >= 3) {
        score += 1;
        components.push('Advanced stage (III/IV)');
    }
    
    // Elevated LDH (assuming ULN of 280)
    if (ldh > 280) {
        score += 1;
        components.push('Elevated LDH');
    }
    
    // Low ANC
    if (anc < 1.5) {
        score += 1;
        components.push('Low ANC (<1.5)');
    }
    
    let riskGroup, riskClass;
    if (score <= 1) {
        riskGroup = 'Low Risk';
        riskClass = 'low';
    } else if (score === 2) {
        riskGroup = 'Intermediate Risk';
        riskClass = 'intermediate';
    } else {
        riskGroup = 'High Risk';
        riskClass = 'high';
    }
    
    // Update display
    document.getElementById('ipi-score-value').textContent = score;
    document.getElementById('ipi-risk-group').textContent = riskGroup;
    document.getElementById('ipi-risk-group').className = `score-interpretation ${riskClass}`;
    
    // Show results
    document.getElementById('ipi-result').style.display = 'block';
    document.getElementById('ipi-result').scrollIntoView({ behavior: 'smooth' });
}
    </script>
</body>
</html>
